View source for Team:ETH Zurich/Circuit/Fb MRI Contrast Agent

{{ETH_Zurich/Head_N_Prefix}}
<html>
<link rel="stylesheet" type="text/css" href="/Template:ETH_Zurich/background_css?action=raw&ctype=text/css">
</html> 
{{ETH_Zurich/Head_N_Suffix}}
{{ETH_Zurich/Header_N}}
<html>
<main role="main">
<h1 class="headline">MRI Contrast Agent</h1>
<section>
<h1>Introduction</h1>


    <p>Since the beginnings of modern medicine, doctors have been eager to see what's happening on the inside of the body rather than to just treat blindly. </p>

    <p>Therefore, it comes as no surprise that one of the characteristics that the ideal bacterial cancer therapeutic should posses is external detectability. The ability to see from the outside what's happening on the inside would allow the doctor to get critical information about the state of the tumor, the success of localization and the efficacy of treatment. <a href="#bib1" class="forward-ref">[1]</a></p>


    <figure class="fig-nonfloat" style="width:40%">
        <img src="https://static.igem.org/mediawiki/2017/9/9e/T--ETH_Zurich--fb_figure1.png">
        <figcaption>Figure 1. MRI scan of the brain, a non-invasive way to take a peak at what's going on inside of the head.</figcaption>
    </figure>

</section>

<section>
<h1>The Imaging Modality</h1>

    <p>To achieve this in CATE, the first step was to choose the imaging modality. Several methods have already been used to visualize contrast-producing bacteria, such as Positron Emission Tomography (PET), Bioluminescence Imaging (BLI), Fluorescence Imaging, Computed Tomography (CT) and Magnetic Resonance Imaging (MRI). <a href="#bib2" class="forward-ref">[2]</a><a href="#bib3" class="forward-ref">[3]</a><a href="#bib4" class="forward-ref">[4]</a> To pick one, we carefully evaluated advantages and disadvantages of these different techniques (Table 1). </p>

    <p>Our final decision - MRI. We chose MRI because it is a well-established imaging method in humans, readily available in the clinics. It offers good spatial resolution and does not use ionizing radiation, which means it is in no way harmful. Finally, focused ultrasound, an integral part of our <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fd_Heat_Sensor">Heat Sensor</a>, uses exclusively MRI image guidance. Therefore, for both theoretical and practical reasons, we decided to incorporate an MRI reporter gene into CATE.</p>

    <table style="width:100%">
<caption>Table 1. Pros and cons of different imaging modalities. BLI = bioluminescence imaging, PET = positron emission tomography, MRI = magnetic resonance imaging, CT =
 computed tomography</caption>
  <tr>
<th></th>
<th>BLI</th>
<th>FLUORESCENCE</th>
<th>PET</th>
<th>MRI</th>
<th>CT</th>
  </tr>
  
  <tr>
<th>PROS</th>
<td>sensitive<br>non-toxic</td>
<td>sensitive<br>non-toxic</td>
<td>suitable for humans<br>very sensitive</td>
<td>suitable for humans<br>spatial resolution<br>non-toxic</td>
<td>suitable for humans<br>spatial resolution<br>temporal resolution</td>
  </tr>

  <tr>
<th>CONS</th>
<td>only small animals</td>
<td>only small animals<br>external light source<br>limited depth</td>
<td>radioactive source<br>expensive<br>spatial resolution</td>
<td>slow (ca. 30 min/scan)<br>expensive<less sensitive than PET</td>
<td>ionizing radiation</td>
  </tr>

</table>

</section>

<section>
<h1>The MRI Reporter</h1>

    <figure class="fig-float" style="float:right; width:500px;">
        <img src="https://static.igem.org/mediawiki/2017/9/96/T--ETH_Zurich--fb_figure2.png">
        <figcaption>Figure 2. Effects of overexpression of different ferritin-like proteins in E. coli Nissle on T2 relaxation rate. R2 relaxation = reciprocal of T2 relaxation, GFP = green fluorescent protein, bfr = bacterioferritin, fri = Dps-type ferritin, ftn = archetypal ferritin, bfr M52L and M52H = heme-deleted bacterioferritins<br>
<!-- TODO: Maybe move the reference to the last section and just put a link here? --> 
        From: Hill, Philip J., et al. <i>PLoS One</i> 6.10 (2011): e25409</figcaption>
    </figure>

    <p>We have looked into several different MRI reporters and <a href="https://2017.igem.org/Team:ETH_Zurich/HP/Gold_Integrated#rudin-interview">consulted professor Markus Rudin</a>, an expert in molecular imaging from the Institute of Biomedical Engineering of ETH. After careful consideration, we choose to work with a ferritin-like bacterial protein, bacterioferritin.</p>



    <p>Ferritins are iron storage proteins found in different species. Through ferroxidase, they convert iron from its toxic, ferrous state (Fe<sup>2+</sup>) into a non-toxic, ferric state (Fe<sup>3+</sup>). When present in its ferric state, iron acts as a paramagnetic agent and causes a shortening of the transversal relaxation (T2) in MRI. Depending on the concentration of iron, this can lead to a visible change in contrast. <a href="#bib5" class="forward-ref">[5]</a></p>

    <p>Bacterioferritin is one of the three forms of ferritin-like proteins found in bacteria. It has been shown that overexpression of bacterioferritin in E. coli Nissle can lead to a visible contrast change in MRI, which allows for visualization of the bacteria (Figure 2). <a href="#bib6" class="forward-ref">[6]</a></p>

</section>

<section>
<h1>Bacterioferritin and CATE</h1>

    <p>In our design, we make bacterioferritin a reporter of passing through <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fa_Tumor_Sensor">Checkpoint 1</a> Once enough bacteria have colonized the tumor and overproduction of lactate has been sensed, the AND-gate of the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fa_Tumor_Sensor">Tumor Sensor</a> is activated. This leads to expression of the MRI Contrast Agent and the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fc_Anti_Cancer_Toxin">Anti-Cancer Toxin</a> (Figure 3). </p>

    <figure class="fig-nonfloat" style="width:800px;">
        <img src="https://static.igem.org/mediawiki/2017/c/c9/T--ETH_Zurich--Circuit_MRI_figure3.png">
        <figcaption>Figure 3. Change in signal generated by expression of bacterioferritin. Once the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fa_Tumor_Sensor">Tumor Sensing</a> has been activated, both the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fc_Anti_Cancer_Toxin">Anti-Cancer Toxin</a> azurin and the MRI Contrast Agent bacterioferritin are produced. Azurin will accumulate inside of the bacteria until it is ready for release. Bacterioferritin will take up iron and produce a change in the T2 signal in MRI.</figcaption>
    </figure>

    <p>While the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fc_Anti_Cancer_Toxin">Anti-Cancer Toxin</a> will accumulate inside of CATE until it is ready to be released during <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fe_Cell_Lysis">Cell Lysis</a>, the MRI Contrast Agent will take up iron and create a change in the MRI signal. The change in the signal will alert the doctor of the following:</p>

    <ul>
        <li>the bacteria have colonized the correct location,</li>
        <li>there is enough bacteria to produce a full dose of the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fc_Anti_Cancer_Toxin">Anti-Cancer Toxin</a>, so the risk of sub-dosing and eventually producing a drug-resistant tumor is minimized and </li>
        <li>the <a href="https://2017.igem.org/Team:ETH_Zurich/Circuit/Fc_Anti_Cancer_Toxin">Anti-Cancer Toxin</a>, located on the same plasmid and under the control of the same promoter as the MRI Contrast Agent, has started to accumulate. </li>
    </ul>

</section>

<section class="references">
    <h1>References</h1>
    <ol>
        <li id="bib1">Forbes, Neil S. "Engineering the perfect (bacterial) cancer therapy." <cite>Nature reviews. Cancer</cite> 10.11 (2010): 785. <a href"=https://doi.org/10.1038/nrc2934">doi: 10.1038/nrc2934</a></li>
        <li id="bib2">Cronin, M., et al. "Bacterial vectors for imaging and cancer gene therapy: a review." <cite>Cancer gene therapy</cite> 19.11 (2012): 731. <a href="https://doi.org/10.1038/cgt.2012.59">doi: 10.1038/cgt.2012.59</a></li>
        <li id="bib3">Gilad, Assaf A., and Mikhail G. Shapiro. "Molecular Imaging in Synthetic Biology, and Synthetic Biology in Molecular Imaging." <cite>Molecular Imaging and Biology</cite> 19.3 (2017): 373-378. <a href="https://doi.org/10.1007/s11307-017-1062-1">doi: 10.1007/s11307-017-1062-1</a></li>
        <li id="bib4">Lyons, Scott K., P. Stephen Patrick, and Kevin M. Brindle. "Imaging mouse cancer models in vivo using reporter transgenes." <cite>Cold Spring Harbor Protocols</cite> 2013.8 (2013): pdb-top069864. <a href="https://doi.org/10.1101/pdb.top069864">doi: 10.1101/pdb.top069864</a></li>
        <li id="bib5">Cohen, Batya et al. “Ferritin as an Endogenous MRI Reporter for Noninvasive Imaging of Gene Expression in C6 Glioma Tumors.” <cite>Neoplasia (New York, N.Y.)</cite> 7.2 (2005): 109–117. Print. <a href="https://doi.org/10.1593/neo.04436">doi: 10.1593/neo.04436</a></li>
        <li id="bib6">Hill, Philip J., et al. "Magnetic resonance imaging of tumors colonized with bacterial ferritin-expressing Escherichia coli." <cite>PLoS One</cite> 6.10 (2011): e25409. <a href="https://doi.org/10.1371/journal.pone.0025409">doi: 10.1371/journal.pone.0025409</a></li>
    </ol>
</section>
</main>
</html>
{{ETH_Zurich/Footer_N}}